Analyst Profile

Followed by 18 followers
.
Emily Bodnar

Emily Bodnar

H.C. Wainwright
Wall Street Analyst
#7,535 out of 8,141 Wall Street Analysts
#22,643 out of 24,284 experts

Success Rate

33%
18 out of 54 transactions made a profit

Average Return

-12.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Emily Bodnar's trades since 2022 and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -12.3% per rating.

Stock Rating Distribution

64Ratings
95.31% Buy
4.69% Hold
0.00% Sell
Distribution of Emily Bodnar's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
CanadaCanadian Market

Best Rating

Stock:
Dice Therapeutics Inc
(DICE)
Rating:Buy
Date:Jul 18, 2022 - Today
Return:+108.40%
The most profitable rating made by Emily Bodnar

Emily Bodnar's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Imunon
Oct 03, 2022
Buy
Assigned
$16.00
(1003.37% Upside)
7Ratings
0%
-37.80%
Purple Biotech
Oct 17, 2022
Buy
Initiated
$7.00
(243.14% Upside)
1Ratings
100%
+3.50%
NovoCure
Oct 28, 2022
Buy
Reiterated
$100.00
(33.33% Upside)
4Ratings
75%
+6.68%
Ventyx Biosciences
Nov 04, 2022
Buy
Reiterated
$50.00
(81.82% Upside)
4Ratings
50%
+10.95%
Olema Pharmaceuticals
Nov 09, 2022
Buy
Reiterated
$12.00
(280.95% Upside)
7Ratings
0%
-26.18%
Nkarta
Nov 10, 2022
Buy
Reiterated
$34.00
(292.16% Upside)
6Ratings
0%
-33.18%
Context Therapeutics
Nov 10, 2022
Buy
Reiterated
$6.00
(337.96% Upside)
8Ratings
29%
-15.97%
SQZ Biotechnologies
Nov 10, 2022
Buy
Reiterated
$10.00
(277.36% Upside)
2Ratings
0%
-6.20%
Dice Therapeutics
Nov 10, 2022
Buy
Reiterated
$60.00
(84.28% Upside)
4Ratings
75%
+39.60%
Femasys
Nov 11, 2022
Buy
Reiterated
$5.00
(287.60% Upside)
7Ratings
43%
-14.50%
List of latest recommendations made by Emily Bodnar. Click to expand and see Emily Bodnar's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >